JP2006514981A - Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法 - Google Patents

Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法 Download PDF

Info

Publication number
JP2006514981A
JP2006514981A JP2004571002A JP2004571002A JP2006514981A JP 2006514981 A JP2006514981 A JP 2006514981A JP 2004571002 A JP2004571002 A JP 2004571002A JP 2004571002 A JP2004571002 A JP 2004571002A JP 2006514981 A JP2006514981 A JP 2006514981A
Authority
JP
Japan
Prior art keywords
independently
alkyl
moiety
following structure
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004571002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514981A5 (https=
Inventor
サミュエル ジェイ． ダニシェフスキー，
バディム ダドキン，
スードン ジェン，
ミハーバラン マンダル，
Original Assignee
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン − ケッタリング インスティチュート フォー キャンサー リサーチ filed Critical スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Publication of JP2006514981A publication Critical patent/JP2006514981A/ja
Publication of JP2006514981A5 publication Critical patent/JP2006514981A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2004571002A 2002-12-03 2003-12-03 Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法 Pending JP2006514981A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43082202P 2002-12-03 2002-12-03
US50016103P 2003-09-04 2003-09-04
US50070803P 2003-09-05 2003-09-05
PCT/US2003/038471 WO2004050711A2 (en) 2002-12-03 2003-12-03 Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof

Publications (2)

Publication Number Publication Date
JP2006514981A true JP2006514981A (ja) 2006-05-18
JP2006514981A5 JP2006514981A5 (https=) 2009-05-14

Family

ID=32475412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004571002A Pending JP2006514981A (ja) 2002-12-03 2003-12-03 Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法

Country Status (6)

Country Link
US (1) US7531181B2 (https=)
EP (1) EP1569955A2 (https=)
JP (1) JP2006514981A (https=)
AU (1) AU2003302235A1 (https=)
CA (1) CA2508539A1 (https=)
WO (1) WO2004050711A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) * 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE60027905T2 (de) 1999-08-20 2007-05-10 Sloan-Kettering Institute For Cancer Research Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
WO2004050711A2 (en) 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
WO2005078443A1 (en) * 2004-02-13 2005-08-25 Inverness Medical Switzerland Gmbh Determination of infection by the immune response to a carbohydrate moiety
KR20080056688A (ko) * 2005-03-16 2008-06-23 유니버시티 오브 옥스퍼드 Ｈｉｖ－ｉ용 만노스 면역원
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
EP2010556B1 (en) 2006-04-11 2015-09-23 Sloan-Kettering Institute for Cancer Research Homogeneous erythropoietin and method for their preparation
TWI432448B (zh) * 2006-09-14 2014-04-01 Univ Duke 疫苗
KR20090103939A (ko) * 2007-01-29 2009-10-01 유나이티드 세러퓨틱스 코오포레이션 당 면역원
ES2360334T3 (es) 2008-06-27 2011-06-03 Theranor Sprl Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus.
EP2315771A4 (en) 2008-07-11 2012-02-01 Sloan Kettering Inst Cancer GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF
US20110136729A1 (en) * 2009-05-26 2011-06-09 Shien Lu Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
US9493580B2 (en) 2010-06-11 2016-11-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
EP2925774B8 (en) 2012-11-29 2018-03-07 The Texas A&M University System Engineering the production of a conformational variant of occidiofungin that has enhanced inhibitory activity against fungal species
EP3191114B1 (en) 2014-09-12 2021-03-03 Mississippi State University Occidiofungin formulations and uses thereof
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (pt) 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US7556806B2 (en) * 2002-10-11 2009-07-07 University Of Maryland Biotechnology Institute Carbohydrate-based synthetic vaccines for HIV
WO2004050711A2 (en) 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
AU2003302165A1 (en) 2002-12-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6009061465, Ｃｈｅｍ． Ｒｅｖ．, 200202, ｖｏｌ．１０２， ｎｏ．２, ｐ．５７９−６０２ *
JPN6009061469, Ｊ． Ｖｉｒｏｌ．, 200207, ｖｏｌ．７６， ｖｏｌ．１４, ｐ．７３０６−７３２１ *
JPN6009061473, Ｊ． Ｖｉｒｏｌ．, 200207, ｖｏｌ．７６， ｖｏｌ．１４, ｐ．７２９３−７３０５ *
JPN6009061478, Ｊ． Ａｍ． Ｃｈｅｍ． Ｓｏｃ．, 1993, ｖｏｌ．１１５， ｎｏ．２３, ｐ．１０５３１−１０５３７ *
JPN6009061480, Ｊ． Ａｍ． Ｃｈｅｍ． Ｓｏｃ．, 1997, ｖｏｌ．１１９， ｎｏ．４６, ｐ．１１１３７−１１１４６ *

Also Published As

Publication number Publication date
CA2508539A1 (en) 2004-06-17
EP1569955A2 (en) 2005-09-07
US7531181B2 (en) 2009-05-12
WO2004050711A3 (en) 2005-01-27
WO2004050711A2 (en) 2004-06-17
AU2003302235A8 (en) 2004-06-23
AU2003302235A1 (en) 2004-06-23
US20060229432A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
JP2006514981A (ja) Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法
AU750701B2 (en) Alpha-O-linked glycoconjugates, methods of preparation and uses thereof
AU758097B2 (en) Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof
US8623378B2 (en) Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
JP2006507233A (ja) 糖質エピトープを含む糖結合体、それらの合成方法、およびガンの処置または予防のためのそれらの使用
Pifferi et al. Cyclopeptide scaffolds in carbohydrate-based synthetic vaccines
US20040208884A1 (en) Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
AU2009268349B2 (en) Glycopeptide constructs and uses thereof
US7645454B2 (en) Prostate specific antigens and uses thereof
US10206988B2 (en) Xenoantigen-displaying anti-cancer vaccines and method of making
WO2006017180A2 (en) Glycopeptide dimers and uses thereof
US11007256B2 (en) Synthetic lipopeptide vaccines and immunotherapeutics
Hevey et al. Conjugation Strategies Used for the Preparation of Carbohydrate‐Conjugate Vaccines
JP2007527864A (ja) 自然に起こる化学的連結による、多官能化ペプチドおよび／またはタンパク質の調製方法
US20210260204A1 (en) Fluoro-tf-muc1 glycopeptide conjugate, preparation method and application thereof
EP0135788A1 (en) Muramyldipeptide active ester derivatives
Karmakar Synthesis and study of MUC1-based anti-tumor vaccines
Pifferi Design and synthesis of multivalent glycoconjugates for anti-cancer immunotherapy
Vepřek Desing and synthesis of Tn-bearing glycodendrimers and their interaction with components of innate and adaptive immunity
Sarkar Synthesis and study of anti-tumor vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110223